<DOC>
	<DOCNO>NCT00963365</DOCNO>
	<brief_summary>The purpose study determine safety AZD6765 give single multiple oral dos compare oral intravenous ( IV ) formulation AZD6765 placebo .</brief_summary>
	<brief_title>AZD6765 Oral Single Ascending Dose/Multiple Ascending Dose ( SAD/MAD )</brief_title>
	<detailed_description />
	<criteria>Healthy volunteer Females must nonchildbearing potential . Any clinically significant illness , medical/surgical procedure trauma within 4 week first administration investigational product . Has receive another new chemical entity ( define compound approve marketing ) participate clinical study include drug treatment within 3 month ( halflife &lt; 24 hour ) first administration study drug Plasma blood product donation within one month screen blood donation/blood loss &gt; 500mL 3 month prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Healthy volunteer</keyword>
</DOC>